HCW Biologics Inc (HCWB)vsJohnson & Johnson (JNJ)
HCWB
HCW Biologics Inc
$1.79
-13.53%
HEALTHCARE · Cap: $11.67M
JNJ
Johnson & Johnson
$232.77
+1.07%
HEALTHCARE · Cap: $536.54B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 1461658% more annual revenue ($96.36B vs $6.59M). JNJ leads profitability with a 21.8% profit margin vs -34.7%. JNJ earns a higher WallStSmart Score of 59/100 (C).
HCWB
Hold43
out of 100
Grade: D
JNJ
Buy59
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for HCWB.
Margin of Safety
-71.4%
Fair Value
$135.80
Current Price
$232.77
$96.97 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 49.4%
Revenue surging 129081.0% year-over-year
Reasonable price relative to book value
Mega-cap, among the largest globally
Every $100 of equity generates 26 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 27.4%
Generating 1.5B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Elevated debt levels
Weak financial health signals
Moderate valuation
Expensive relative to growth rate
Earnings declined 52.9%
Comparative Analysis Report
WallStSmart ResearchBull Case : HCWB
The strongest argument for HCWB centers on Operating Margin, Revenue Growth, Price/Book. Revenue growth of 129081.0% demonstrates continued momentum.
Bull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.8% and operating margin at 27.4%.
Bear Case : HCWB
The primary concerns for HCWB are EPS Growth, Market Cap, Debt/Equity.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Key Dynamics to Monitor
HCWB profiles as a hypergrowth stock while JNJ is a mature play — different risk/reward profiles.
HCWB carries more volatility with a beta of 1.14 — expect wider price swings.
HCWB is growing revenue faster at 129081.0% — sustainability is the question.
JNJ generates stronger free cash flow (1.5B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (59/100 vs 43/100), backed by strong 21.8% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
HCW Biologics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
HCW Biologics Inc is a pioneering biotechnology firm focused on advancing immunotherapies and vaccine technologies to tackle critical health issues like cancer and infectious diseases. By utilizing proprietary platforms designed to optimize immune response, the company is developing a promising pipeline of clinical candidates that aim to revolutionize patient treatment. With strategic partnerships and a dedication to fulfilling unmet medical needs, HCW Biologics stands at the forefront of the biotechnology industry, representing a compelling investment opportunity amid the sector's growth.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?